Novartis CEO Vas Narasimhan stated that the company will not compete in the "frenzy" of the weight loss drug market dominated by Novo Nordisk and Eli Lilly. Novartis will instead focus on areas where it can build a “unique position,” including treatments for diseases like Alzheimer’s, Parkinson’s, and various cancers. The company is particularly optimistic about its therapies for cancer, which could become a $20 billion business.
Category
🗞
NewsTranscript
00:00It's Benzinga, and here's what's on the block.
00:03Novartis CEO Bas Norishimen stated that the company will not compete in the weight loss
00:07drug market frenzy dominated by Novo Nordisk and Eli Lilly.
00:11Novartis will instead focus on areas where it can build a unique position, including
00:15treatments for diseases like Alzheimer's, Parkinson's, and various cancers.
00:20The company is particularly optimistic about its therapies for cancer, which could become
00:24a $20 billion business.
00:25For all things money, visit Benzinga.com.